HMGB1 and neoplasm: Developing HMGB1 as a vaccine for PCa is a feasible immunotherapeutic strategy as the previous study strongly support that peptides derived from HMGB1 engrafted in liposomes induced potent antigen-specific and tumor specific immunity against B16-OVA melanoma model [103].